Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) announced the launch of cobas 6500, a fully automated urine testing system.

Cobas 6500 consists of two modular analyzers combining urine strip testing and digital urinary microscopy. The system is designed to test for 23 parameters which help in diagnosing diseases such as urinary tract infection, kidney disease, and diabetes.

The test is expected to ensure high-quality results, increase laboratory productivity significantly along with reducing manual steps and contamination risks for laboratory staff.

The system will be available in Europe, the Asia Pacific region, the Middle East, Africa and Latin America.

Roche is planning to submit an application for the approval of cobas 6500 system in the U.S.

We remind investors that Roche is a leader in drugs for oncology, immunology and infectious diseases. Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases.

Roche has a broad portfolio of diagnostic tests with more than a hundred high-quality Elecsys assays for immune testing along with a new generation of fully automated cobas analyzers for improved medical decision making, scheduling and efficiency.

The Diagnostics division generated sales of $10.5 billion in 2013, up 4% from a year ago. We are encouraged by Roche’s efforts to further strengthen its Diagnostic division which should boost sales.

Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader healthcare sector include Regeneron Pharmaceuticals (REGN - Analyst Report), Shire (SHPG - Analyst Report) and Allergan (AGN - Analyst Report).

While Regeneron Pharma carries a Zacks Rank #1 (Strong Buy), Shire and Allergan carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%